{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:15:13Z","timestamp":1790172913529,"version":"4.1.0"},"reference-count":29,"publisher":"Japan Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1507\/endocrj.ej18-0491","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T18:42:03Z","timestamp":1552588923000},"page":"515-522","source":"Crossref","is-referenced-by-count":25,"title":["Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells"],"prefix":"10.1507","volume":"66","author":[{"given":"Yuko","family":"Asari","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036-8562, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Kageyama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036-8562, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036-8562, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Kogawa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036-8562, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Niioka","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036-8562, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Daimon","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036-8562, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Kageyama K, Oki Y, Sakihara S, Nigawara T, Terui K, et al. (2013) Evaluation of the diagnostic criteria for Cushing\u2019s disease in Japan. Endocr J 60: 127\u2013135.","DOI":"10.1507\/endocrj.EJ12-0299"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, et al. (2008) The diagnosis of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93: 1526\u20131540.","DOI":"10.1210\/jc.2008-0125"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, et al. (2008) Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome; a consensus statement. J Clin Endocrinol Metab 93: 2454\u20132462.","DOI":"10.1210\/jc.2007-2734"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Bertagna X, Guignat L (2013) Approach to the Cushing\u2019s disease patient with persistent\/recurrent hypercortisolism after pituitary surgery. J Clin Endocrinol Metab 98: 1307\u20131318.","DOI":"10.1210\/jc.2012-3200"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Rhode PR, Gorski J (1991) Growth and cell cycle regulation of mRNA levels in GH3 cells. Mol Cell Endocrinol 82: 11\u201322.","DOI":"10.1016\/0303-7207(91)90004-C"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Schteingart DE (2009) Drugs in the medical treatment of Cushing\u2019s syndrome. Expert Opin Emerg Drugs 14: 661\u2013671.","DOI":"10.1517\/14728210903413522"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, et al. (2015) Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease. Nat Genet 47: 31\u201338.","DOI":"10.1038\/ng.3166"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Ma ZY, Song ZJ, Chen JH, Wang YF, Li SQ, et al. (2015) Recurrent gain-of-function USP8 mutations in Cushing\u2019s disease. Cell Res 25: 306\u2013317.","DOI":"10.1038\/cr.2015.20"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Theodoropoulou M, Arzberger T, Gruebler Y, Jaffrain-Rea ML, Schlegel J, et al. (2004) Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J Endocrinol 183: 385\u2013394.","DOI":"10.1677\/joe.1.05616"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, et al. (2011) EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest 121: 4712\u20134721.","DOI":"10.1172\/JCI60417"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, et al. (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16: 15\u201331.","DOI":"10.1517\/14728222.2011.648617"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, et al. (2007) Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and\/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25: 3978\u20133984.","DOI":"10.1200\/JCO.2007.11.8612"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Bonde GV, Yadav SK, Chauhan S, Mittal P, Ajmal G, et al. (2018) Lapatinib nano-delivery systems: a promising future for breast cancer treatment. Expert Opin Drug Deliv 15: 495\u2013507.","DOI":"10.1080\/17425247.2018.1449832"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Liu X, Kano M, Araki T, Cooper O, Fukuoka H, et al. (2015) ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice. Endocrinology 156: 71\u201379.","DOI":"10.1210\/en.2014-1627"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Kageyama K, Hanada K, Suda T (2009) Differential regulation of urocortins1-3 mRNA in human umbilical vein endothelial cells. Regul Pept 155: 131\u2013138.","DOI":"10.1016\/j.regpep.2009.02.012"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Kageyama K, Hanada K, Suda T (2010) Differential regulation and roles of urocortins in human adrenal H295R cells. Regul Pept 162: 18\u201325.","DOI":"10.1016\/j.regpep.2010.02.006"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Asari Y, Kageyama K, Nakada Y, Tasso M, Takayasu S, et al. (2017) Inhibitory effects of a selective Jak2 inhibitor on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT20 cells. Onco Targets Ther 10: 4329\u20134338.","DOI":"10.2147\/OTT.S141345"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Murasawa S, Kageyama K, Sugiyama A, Ishigame N, Niioka K, et al. (2014) Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation <i>in vitro<\/i> and <i>in vivo<\/i>. Mol Cell Endocrinol 394: 37\u201346.","DOI":"10.1016\/j.mce.2014.07.001"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Kageyama K, Sugiyama A, Murasawa S, Asari Y, Niioka K, et al. (2015) Aphidicolin inhibits cell proliferation <i>via<\/i> the p53-GADD45\u03b2 pathway in AtT-20 cells. Endocr J 62: 645\u2013654.","DOI":"10.1507\/endocrj.EJ15-0084"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Pei L, Melmed S (1997) Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11: 433\u2013441.","DOI":"10.1210\/mend.11.4.9911"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, et al. (1999) Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84: 761\u2013767.","DOI":"10.1210\/jcem.84.2.5432"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Chesnokova V, Zonis S, Zhou C, Ben-Shlomo A, Wawrowsky K, et al. (2011) Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One 6: e17924.","DOI":"10.1371\/journal.pone.0017924"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Chesnokova V, Zonis S, Wawrowsky K, Tani Y, Ben-Shlomo A, et al. (2012) Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth. Mol Endocrinol 26: 2092\u20132103.","DOI":"10.1210\/me.2012-1158"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Hern\u00e1ndez A, L\u00f3pez-Lluch G, Navas P, Pintor-Toro JA (2009) HDAC and Hsp90 inhibitors down-regulate PTTG1\/securin but do not induce aneuploidy. Genes Chromosomes Cancer 48: 194\u2013201.","DOI":"10.1002\/gcc.20630"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Nakada Y, Kageyama K, Sugiyama A, Desaki R, Takayasu S, et al. (2015) Inhibitory effects of trichostatin A on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT-20 cells. Endocr J 62: 1083\u20131090.","DOI":"10.1507\/endocrj.EJ15-0369"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Sugiyama A, Kageyama K, Murasawa S, Ishigame N, Niioka K, et al. (2014) Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells. Pituitary 18: 542\u2013553.","DOI":"10.1007\/s11102-014-0607-4"},{"key":"27","unstructured":"27 Andl CD, Mizushima T, Oyama K, Bowser M, Nakagawa H, et al. (2004) EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes. Am J Physiol Gastrointest Liver Physiol 287: G1227\u2013G1237."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Zheng Q, Han L, Dong Y, Tian J, Huang W, et al. (2014) JAK2\/STAT3 targeted therapy suppresses tumor invasion <i>via<\/i> disruption of the EGFRvIII\/JAK2\/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma. Neuro Oncol 16: 1229\u20131243.","DOI":"10.1093\/neuonc\/nou046"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Araki T, Liu X, Kameda H, Tone Y, Fukuoka H, et al. (2017) EGFR induces E2F1-mediated corticotroph tumorigenesis. J Endocr Soc 1: 127\u2013143.","DOI":"10.1210\/js.2016-1053"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/6\/66_EJ18-0491\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T23:36:55Z","timestamp":1561765015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/6\/66_EJ18-0491\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej18-0491","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}